Introduction: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFRmutated NSCLC. Estimating differences in toxicity between these EGFR TKIs is important for personalizing treatment.
Introduction
EGFR tyrosine kinase inhibitor (TKI) therapy is the current standard-of-care treatment for advanced NSCLC with activating mutations of the EGFR gene. Three orally administered EGFR TKIs have been approved internationally: the first-generation TKIs gefitinib and erlotinib and the second-generation TKI afatinib. Gefitinib and erlotinib are reversible EGFR TKIs, whereas afatinib is an irreversible ErbB family blocker that blocks signaling from ErbB family receptors by binding covalently to proteins of the ErbB receptor network and irreversibly abrogates signaling. 1, 2 All three agents are widely used in routine clinical practice.
In personalizing care for patients with advanced EGFR-mutant NSCLC, the treatment decision should ideally be based on assessing differences in effectiveness of each EGFR TKI against the trade-off of differences in treatment-related toxicities (TRTs). Few trials have directly compared EGFR TKIs to address this need. For first-generation EGFR TKIs, no trial has reported a direct comparison of gefitinib versus erlotinib in the first-line setting. Two trials 3, 4 that compared these agents in the second-line setting have reported similar progression-free survival (PFS) for both, with different toxicity profiles. In a direct head-to-head comparison of second-versus first-generation EGFR TKIs, the LUXLung 7 trial reported statistically significant improvement for PFS with afatinib over gefitinib but higher drug-related severe adverse events (AEs) (10.6% with afatinib versus 4.4% with gefitinib), 5 yet the rates of discontinuation due to a drug-related AE were the same.
Maintaining and improving quality of life in advanced EGFR-mutant NSCLC is just as important a treatment goal as prolongation of survival. Given that TRT could substantially impair quality of life and patients might value trade-offs between benefits and TRT 6 differently, oncologists are challenged with counseling patients and recommending the most appropriate EGFR TKI. Evidence on the relative risk for TRT remains limited because severe TRTs are rare and individual studies are not powered to detect differences in rare events. Furthermore, where data are available, simple approaches of presenting the trade-off between treatment benefit and harm and the uncertainty surrounding these estimates to patients are not yet sufficiently well developed to inform these discussions.
To address this clinical need, we performed a metaanalysis to quantify the relative differences in toxic death, grade 3 or 4 (G3/4) adverse events (AEs), and discontinuation of treatment because of drug-related AEs with gefitinib, erlotinib, and afatinib. We also demonstrated the use of a risk-benefit contour as a decision aid tool to present the trade-off between the efficacy and toxicity of different EGFR TKIs to inform clinical decisions about the choice of EGFR TKI.
Methods
A systematic search of MEDLINE, the Excerpta Medica Database, and the Cochrane Central Register of Controlled Trials databases was undertaken by using the following terms: lung neoplasms, non-small-cell lung cancer, gefitinib, erlotinib, afatinib, EGFR, epidermal growth factor receptor, phase 3, phase 2, clinical trial, randomized controlled trial, controlled clinical trial, systematic review, and meta-analysis with the dates January 2004 to December 2015. Searches were limited to human studies published in English. When multiple publications of the same clinical trial were encountered, only the most recent or complete trial report was included.
Studies that met the following criteria were included: randomized phase 2 or 3 trial with prospective recruitment of treatment-naive patients with advanced NSCLC, an EGFR TKI (gefitinib, erlotinib, or afatinib) arm, and the National Cancer Institute's Common Terminology Criteria for Adverse Events used to report toxicity. Only first-line studies that compared EGFR TKI monotherapy with any chemotherapy, placebo, or best supportive care were included. Trials in which EGFR TKIs were administered in a pulse regimen, with intermittent scheduling, or as sequential/combination treatment with chemotherapy were excluded.
Trial characteristics, including EGFR TKI type and duration of EGFR TKI therapy, were extracted along with summary information on patient characteristics (age, sex, performance status [PS], ethnicity, and smoking status).
The number of deaths related to EGFR TKI therapy (toxic death), overall G3/4 AEs, and discontinuation of treatment because of AEs were extracted from the EGFR TKI arm from each trial. Overall, G3/4 AEs was defined as the number of patients experiencing at least one episode of any G3/4 AE during the study. Data on specific individual AEs of particular relevance for EGFR TKI therapy were also identified.
We assessed the extent to which trials met recommendations made by the CONSORT statement extension for AE reporting. 7 Data were extracted independently by two authors (P.D. and S.L.). Any discrepancies were resolved by consensus.
Statistical Analysis
The pooled risk for toxic death, G3/4 AEs, and discontinuation of treatment were expressed as the total number of cases for each of these outcomes divided by the total number of patients treated with the same EGFR TKI from different trials. We performed indirect comparisons to estimate the relative risks (RRs) computed as the ratio of the risks for the following three comparisons: gefitinib versus afatinib, erlotinib versus afatinib, and gefitinib versus erlotinib. The MantelHaenszel fixed effect method 8, 9 was used to obtain the pooled RR and the corresponding 95% confidence interval (CI).
We applied the same method to examine common types of AEs associated with EGFR TKI therapy for all grades. A subgroup analysis compared trials that included patients with poor PS (defined as >80% of patients with PS 2) versus those with good PS (defined as >80% of patients with PS <2). We performed sensitivity analyses by repeating the analysis in trials that included only patients who had upfront testing and confirmation of EGFR mutation at study entry, because we recognized that a significant proportion of patients included in this study did not have EGFR activating mutation and may have had a shorter duration of treatment and poorer PS, which could have influenced the degree of TRT they experienced. In contrast, patients with EGFR mutation are more likely to benefit from EGFR TKI therapy and may have a longer duration of treatment and hence a greater chance of experiencing toxicities. In a second sensitivity analysis, we excluded studies that reported a substantially greater risk for AEs than other studies, as these studies might have skewed the results.
We used the c 2 Cochran Q test to detect any heterogeneity across the different trials for TRT overall and by treatment type.
We developed a clinical significance curve and riskbenefit contour to illustrate how the trade-off between differences in trial estimates of treatment benefit versus toxicity with different EGFR TKIs can be presented to inform treatment choices in practice. The method of how to develop a risk-benefit contour has previously been described. 10 In brief, it can be used as a decision aid tool by allowing the clinician to read off the probability of achieving a specified minimum size of treatment benefit (for example, the percentage of relative improvement in PFS) at a specified acceptable maximum toxicity rate (e.g., additional percentage of risk for G3/4 AEs). The clinician can then use the probability of achieving this predefined risk-benefit trade-off to counsel patients about the choice between an agent that offers an improved likelihood of extending PFS versus one that carries a lower risk for toxicity. The size of the minimum acceptable treatment benefit and maximum acceptable toxicity can be varied by the clinician for each individual patient. For the purpose of presenting an illustrative example, we used the results of LUX-Lung 7 to estimate the additional clinical benefit of afatinib versus gefitinib 5 and the results of the present meta-analysis to estimate the difference in G3/4 AEs between these agents.
The nominal level of significance was set at 5%. All 95% CIs were two sided. No corrections were made for multiple testing. Cochrane Review Manager version 5.1 (Cochrane Collaboration, Copenhagen, Denmark) was used for the analyses.
Results
Sixteen trials with a total of 2535 patients randomly assigned to receive an EGFR TKI ( Fig. 1) were eligible. Two trials 11, 12 investigated afatinib, seven [13] [14] [15] [16] [17] [18] [19] gefitinib, and another seven [20] [21] [22] [23] [24] [25] [26] erlotinib. Of these, seven trials 11, 12, 17, 19, 21, 23, 26 with a total of 1666 patients (34%) had upfront testing and confirmation of EGFR mutation at study entry. Patient age, ethnicity, and baseline PS varied between trials. Median trial population age ranged from 57 to 77 years, and eight trials 11, 13, 15, 17, 19, 20, 23, 26 were conducted with Asian-only populations. In 10 trials, [11] [12] [13] 15, 17, 19, 21, 23, 25, 26 at least 85% of patients had a PS of 0 or 1; four trials 16, 18, 22, 24 recruited 529 patients (20.9%) with a PS of 2 or higher ( Table 1) .
All the trials used the Common Terminology Criteria for Adverse Events, version 3, to grade AEs and described withdrawals due to AE. None reported the duration of AEs or recurrent AEs. Only three 11, 18, 24 described the timing of AE monitoring, and eight described AE-related monitoring and stopping rules. reported methods for presentation and analysis of AErelated information. Nine 11, 12, 14, [17] [18] [19] 22, 24, 26 provided an explicit and balanced discussion of treatment benefits and harm. The risk for publication bias was assessed to be low, as the primary purpose of all included trials was to assess for effectiveness but not toxicity. Tests for heterogeneity by treatment type are not presented on account of the small numbers of trials available for these analyses.
Fifteen trials (with a total of 2201 patients) reported toxic death events and 37 cases (1.7%) were identified. The risk for toxic death was 2.3% with gefitinib (95% CI: 1.6%-3.4%), 0.8% with erlotinib (95% CI: 0.2%-1.9%), and 1.1% with afatinib (95% CI: 0.4%-2.5%). Of the 17 reported causes of death, the most frequent cause of toxic death was pneumonitis (n ¼11 [65%]). In pairwise comparisons, there was no statistically significant difference in risk between the three EGFR TKIs (Fig. 2Ai,  2Bi , and 2Ci).
Fifteen trials (a total of 2391 patients) reported overall G3/4 AEs, and 958 cases (40%) were identified. The risk for G3/4 AEs was 29.1% with gefitinib (95% CI: 26.0%-32.4%), 54.1% with erlotinib (95% CI: 49.1%-59.4%), and 42.1% with afatinib (95% CI: 36.4%-48.4%). Fewer patients had G3/4 AEs when treated with gefitinib than with erlotinib (RR ¼ 0.54, 95% CI: 0.48-0.60, p < 0.01) (Fig. 2Ciii) and with afatinib than with erlotinib (RR ¼ 0.78, 95% CI: 0.69-0.88, p < 0.01) (Fig. 2Cii) . More patients had G3/ 4 AEs when treated with afatinib than with gefitinib (RR ¼ 1.45, 95% CI: 1.26-1.66, p < 0.01) (Fig. 2Ci) .
Fifteen trials (a total of 2319 patients) reported discontinuation of treatment on account of AEs, and 178 cases (7.7%) were identified. The risk for discontinuation of treatment was 7.8% with gefitinib (95% CI: 6.2%-9.6%), 7.2% with erlotinib (95% CI: 5.5%-9.3%), and 8.3% with afatinib (95% CI: 5.9%-11.4%). In pairwise comparisons, there was no statistically significant difference in the risk for discontinuation of treatment between the three EGFR TKIs (Fig. 2Aiii, 2Biii, and 2Ciii) .
Among the EGFR TKI-specific toxicities of all grades, diarrhea (53.3%) and rash (66.5%) were the most frequent, affecting more than half the patients. When compared with gefitinib, afatinib resulted in significantly higher risks for diarrhea (91.7% versus 44.4%, p < 0.01), rash (84.8% versus 62.0%, p < 0.01), stomatitis (61.8% versus 21.8%, p < 0.01), and paronychia (44.4% versus 15.9%, p < 0.01). In contrast, gefitinib was associated with significantly higher risks for increased liver enzyme levels (61.7% versus 20.1%, p < 0.01), nausea (12.6% versus 18.7%, p < 0.01), pruritus (14.7% versus 23.8%, p < 0.01), and appetite loss (15.2% versus 22.6%, p < 0.01) than afatinib was (Fig. 3A) .
When compared with erlotinib, afatinib also resulted in significantly higher risks for diarrhea (91.7% versus 42.4%, p < 0.01), rash (84.8% versus 62.0%, p < 0.01), stomatitis (61.8% versus 16.2%, p < 0.01), and paronychia (44.4% versus 10.4%, p < 0.01). In contrast, erlotinib was associated with a significantly higher risk for fatigue (36.9% versus 13.7%, p < 0.01) and appetite loss (25.2% versus 15.2%, p < 0.01) than afatinib (Fig. 3B) .
When compared with gefitinib, erlotinib resulted in a significantly higher risk for fatigue (17.5% versus 43.1%, p < 0.01). Gefitinib was associated with higher risks for increased liver enzyme levels (61.7% versus 17.8%, p < 0.01), stomatitis (21.8% versus 16.2%, p ¼ 0.01), nausea (18.7% versus 12.6%, p < 0.01), dry skin (28.5% versus 9.1%, p < 0.01), and pruritus (23.8% versus 10%, p < 0.01) than erlotinib (Fig. 3C) .
Supplementary Figure 1 presents these comparisons of individual toxicities separately for grade 1/2 and G3/4 AEs. Note: This table summarizes 16 studies that examined a total of 4888 patients, including 2535 patients in the EGFR TKI arm. The median duration of EGFR TKI treatment was 5.7 months. The median patient age was 64 years (range, 24-91 years. Asians comprised 68% of all patients studied; 41% of those studied were male, 42% were current or former smokers, and 76% had an ECOG PS of 0 or 1. a For those studies in which median duration of EGFR TKI therapy was not known, median PFS is reported instead. b Median age was not known, so mean age is reported instead. CisG, cisplatin-gemcitabine; CisPem, cisplatin-pemetrexed; CisP, cisplatin-paclitaxel; CP, carboplatin-paclitaxel; CG, carboplatin-gemcitabine; CV, carboplatin-vinorelbine; G, gemcitabine; D, docetaxel; V, vinorelbine; Pem, pemetrexed; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival; TKI, epidermal tyrosine kinase inhibitor; NK, not known.
Trials with patients having a good PS reported a lower risk for G3/4 AEs than trials with patients having a poor PS (34.7% versus 58.8%, p < 0.01 [ Supplementary Fig. 2ii] ) and a lower risk for discontinuation of treatment (6.9% versus 10.2%, p ¼ 0.01 [ Supplementary Fig. 2iii] ), but there was no significant difference in the risk for toxic death ( Supplementary  Fig. 2i) .
In sensitivity analysis, there was also no significant difference in the risk for toxic death and overall G3/4 AEs between different EGFR TKIs in trials that included only patients with upfront testing and confirmation of EGFR mutation at study entry (n ¼ 1666) ( Supplementary  Fig. 3 ). However, in this subgroup of trials, there was a higher risk for discontinuation of treatment with afatinib that with erlotinib (8.3% versus 2.9%, p < 0.01 [ Supplementary Fig. 3Biii] ) and with gefitinib than with erlotinib (12.9% versus 2.9%, p < 0.01 [ Supplementary  Fig. 3Ciii]) .
The TOPICAL trial 24 was excluded as a sensitivity analysis because it reported a substantially higher risk for overall G3/4 AEs (75.4%) than the median risk for 35.8% for the other trials. The remaining 15 trials had a greater risk for overall G3/4 AEs with afatinib than with gefitinib (42.1% versus 29.1%, p < 0.01 [ Supplementary Fig. 4Aii]) , and greater risk for discontinuation of treatment with afatinib than with erlotinib (8.3% versus 3.8%, p < 0.01 [ Supplementary Fig. 4Biii]) . Gefitinib was associated with a higher risk for toxic death (2.3% versus 0.8%; p ¼ 0.03 [ Supplementary  Fig. 4Ci] ) and discontinuation of treatment (7.8% versus 3.8%, p < 0.01 [ Supplementary Fig. 4Ciii] April 2017 TRT Risk and EGFR TKIs: Meta-analysiserlotinib, but erlotinib was associated with a higher risk for overall G3/4 AEs (39% versus 29.1%, p < 0.01 [ Supplementary Fig. 4Cii]) . The risk-benefit contour (Fig. 4) shows the benefit of afatinib over gefitinib estimated as a 27% risk reduction of disease progression from LUX-Lung 7, 5 with the additional risk for toxicity estimated as an absolute increase in treatment-related G3/4 AEs of 13% from our meta-analysis (Fig. 2Ci) . To demonstrate the interpretation of the risk-benefit contour, consider a 40-year-old patient with a PS of 0. A physician may decide to recommend afatinib over gefitinib for this patient when there is at least a modestly favorable probability of 60% in achieving a minimum relative PFS benefit of 10% with a maximum additional 15% risk for a G3/4 AE with afatinib versus with gefitinib. The probability of achieving this risk-benefit trade-off can be determined from Figure 4 by drawing a vertical line up from 10% relative PFS benefit on the x axis and a horizontal line out from the 15% maximum additional risk for a G3/4 AE on the y axis. Where these two lines intersect (dashed line, point A), the closest contour line represents the probability of achieving the specified risk-benefit trade-off. In this example, point A lies above the 60% risk-benefit contour line, so trial evidence suggests that there is at least a 60% probability that the physician-defined minimally acceptable trade-off for recommending afatinib will be achieved. In contrast, for an 80-year-old patient with a PS of 2, the same physician may require a higher level of confidence for a favorable 4 and absolute overall treatment-related grade 3 and 4 adverse events. Dashed line is the physician's estimate of the additional anticipated benefit and maximum additional adverse event rates acceptable for a 40-year-old patient assessed as having a performance status of 0. Dotted line is the physician's estimate of additional anticipated benefit and maximum additional adverse event rates acceptable for an 80-year-old patient assessed as having a performance status of 2.
Afatinib vs Erlotinib
risk-benefit trade-off to recommend afatinib over gefitinib. According to the risk-benefit contour, trial evidence suggests that there is a 90% probability of achieving the same relative PFS benefit of 10% with a maximum additional 20% of G3/4 AEs (dotted line, point B). The decision to choose afatinib over gefitinib will therefore depend on whether the physician and patient believe that this trade-off is acceptable.
Discussion
In this meta-analysis, we have demonstrated that toxic deaths across all three EGFR TKIs are low (1.7%), with most deaths occurring secondary to pneumonitis. All three drugs appeared to be well tolerated, with similar rates of discontinuation of treatment of less than 10%. Diarrhea and rash of all grades, which occurred in more than half the patients, were the most frequent types of toxicities.
This meta-analysis reports different toxicity profiles for the different EGFR TKIs. We found that afatinib had an overall higher risk for a G3/4 AE than gefitinib but not erlotinib. The RR for G3/4 AEs with afatinib versus with gefitinib was reported as 1.09 (95% CI: 0.89-1.33) in the LUX-Lung 7 trial, 5 which is consistent with the finding from this meta-analysis (RR ¼ 1.45, 95% CI: 1.26-1.66).
The LUX-Lung 7 trial 5 and this meta-analysis both showed a higher incidence of all grades of diarrhea with afatinib than with gefitinib. Interestingly, the LUX-Lung 7 trial 5 reported a higher incidence of all grades of rash with gefitinib (81.1% versus 62.0%) but a lower incidence of abnormal liver function (25.1% versus 61.7%), unlike our study. In the second-line setting, a Japanese trial 4 also reported fewer G3/4 AEs with gefitinib than with erlotinib (RR ¼ 0.82), which is consistent with our meta-analysis finding for the first-line setting (RR ¼ 0.54). The rate of rash of all grades was significantly higher in the erlotinib arm of that trial (92.4%), unlike in our study (62.0%). However, the Japanese trial 4 and this meta-analysis reported similar risks for diarrhea with both erlotinib and gefitinib. With more than 2500 patients from 16 randomized trials, the data generated from this meta-analysis provides precision that could not be easily achieved from any single trial. Despite the limitation of using indirect comparisons, 27 this meta-analysis demonstrates findings consistent with the more limited evidence available from head-tohead studies of different EGFR TKIs.
Pneumonitis is a toxicity of interest as it accounts for more than half of all toxic deaths in our study. A retrospective study of the Japanese population reports a risk for pneumonitis of 3.5% and mortality of 1.6%, 28 which were higher than those observed in this study (risk for pneumonitis of 1.7% and mortality of 0.5%). The reason for the differences in results observed between this Japanese study and our meta-analysis is not entirely clear. Future research should focus on identifying risk factors for development of pneumonitis.
In addition to summarizing TRT from EGFR TKIs, we also demonstrate an innovative evidence-based approach for evaluating the trade-off between treatment efficacy and toxicity. Cancer patients' involvement in the treatment decision making process is usually suboptimal, 29, 30 but patient involvement can improve satisfaction and confidence in the decisions made. 31 A systematic review of lung cancer patients' preferences found that even small survival benefits are sufficient to justify chemotherapy for advanced or metastatic NSCLC, 6 but patients' preferences vary according to stage of disease, toxicity of chemotherapy, and ethnicity. In contrast to short-term chemotherapy, EGFR TKIs are administered on a daily basis over longer duration. With longer-term continuous therapy, patients will experience chronic TRT, and hence information about the risk-benefit trade-off would be even more important for individualizing their own treatment. We propose that the risk-benefit contour (Fig. 4) be utilized to incorporate the patient's willingness to accept the risk for TRT and the level of uncertainty of benefit when choosing EGFR TKI therapy.
The study has several limitations. First, the data presented on treatment-related G3/4 AEs were based on the single most severe event for each patient. Without access to individual patient data, we are unable to account for duration of therapy because those who were receiving treatment longer would have had a higher chance of experiencing TRT. We were also unable to determine the frequency of recurrence. The current approach in reporting AEs in clinical trials remains inadequate for treatments with chronic administration 32 ; hence, the overall burden of TRT remains underappreciated. Second, the severity of AEs, as reported in this meta-analysis, was based on physicians' but not patients' rating. A previous study that compared physicians' and patients' reporting of TRT demonstrated underreporting of toxicities in clinical trials by physicians. 33 Third, the primary objective of all the included trials was to assess EGFR TKI efficacy, and therefore data collection and reporting on TRT may be less rigorous and could lead to an underestimation of the risk of toxicity, as highlighted in a recent systematic review of oncology trials. 34 Furthermore, all the trials in this metaanalysis reported only on individual toxicities that occurred in at least 5% to 10% of patients, so very rare AEs could not be quantified. Fourth, we have not included other published single-arm and nonrandomized prospective first-line trials of EGFR TKIs; instead, we have included only randomized controlled trials that compared EGFR TKIs with any chemotherapy, placebo, or best supportive care. This is because randomized controlled trials have a more stringent and consistent study design, which would ensure consistency of toxicity reporting across the included trials. Finally, variation in the patient characteristics between trials is a potential source of selection bias for our estimates of the differences in TRT between agents given that these are based on indirect comparisons.
The two major factors that may limit the generalizability of our study findings to real-world clinical practice are differences in patient characteristics between trial and clinic populations and potential improvements in the management of toxicities over time. The TRT rates reported in this study might underestimate the rates as observed in routine clinical practice owing to differences in the baseline characteristics and comorbidities of trial and routine care patients. Although the wide range of patients' ages in the trial populations are representative of routine care populations, most of the trial patients had a good baseline PS. Hence, generalizability of the results of this meta-analysis to routine care patients with a PS of 2 or higher is limited. The management of toxicities may also improve over time with experience gained from earlier studies (e.g., though early recognition and treatment of potentially fatal AEs such as pneumonitis). There might also be lower thresholds with initiation of ancillary treatments for chronic nonfatal TRT such as rash. Thus, the rates of TRT might be lower in clinical trials conducted in later years and more representative of current practice. Unfortunately, the trials did not report management strategies to reduce the severity and recurrence of AEs, such as dose reduction, treatment delay, and ancillary therapies to allow an assessment of generalizability to current practice.
In conclusion, although more than half of the patients treated with an EGFR TKI experience some degree of diarrhea and rash, EGFR TKIs are well tolerated, with less than 10% of instances of discontinuation of treatment being due to AEs. The toxicity profiles vary between EGFR TKIs and can be used to inform the choice of treatment for advanced EGFR-mutated NSCLC. This requires explicit discussions with patients of the trade-offs between the additional benefits and the risk for additional TRT with one EGFR TKI over another.
